Abstract:The early detection of cancer in an asymptomatic population requires the discovery of markers with a very high degree of sensitivity and specificity. While samples obtained from tissue biopsy offer the potential for increased amounts of material for study, a clinical assay must be based on a readily available biofluid such as plasma or urine. The new NCI Alliance of Glycobiologists is approaching this ambitious goal from several directions which range from approaches such as the discovery of a glycan (glycoprotein) biomarker to combinations of disease specific autoantibodies. Mechanisms underlying disease pathogenesis include processes such as cytokine production in inflammation, upregulation of disease specific metalloproteases and metastatic processes that involve cellular migration and tissue breakdown. Such processes may result in the production of disease-related molecular markers, such as acute phase proteins, cytoskeletal fragments and autoantigens. In breast cancer, disease progression has been shown to involve increased levels of glycoproteins related to these categories, as well as altered glycosylation states. At present, in plasma proteomics the isolation of glycoproteins at the level sufficient for extensive glycan characterization will be limited to the more abundant plasma proteins. These proteins would be expected to be primarily derived from the liver, although other tissue specific, and even disease related, glycans would be expected to be part of the population of glycoforms. In an attempt to achieve the necessary sensitivity to detect minor glycoforms present in a selected glycoprotein, we have used a solid phase assay developed by the Haab laboratory in which the candidate biomarkers are captured with specific antibodies and glycan composition differences are probed with a panel of lectins to identify glycoylation changes in such markers. The glycoprotein candidates were identified in the Hancock laboratory by the use of the multiple lectin affinity chromatography (M-LAC) platform to study the plasma glycoproteome in breast cancer patients and healthy donors. In addition, lectin blotting studies were performed on SDS-PAGE gel separations of plasma samples. A third approach explored the glycan changes in a group of abundant plasma glycoproteins isolated by antibody based depletion columns. This paper will present results from these different approaches for the identification of candidate glycoproteins as well as the screening of patient plasma samples and glycoprotein standards.

Aptamer Biorecognition and Gold Nanoshell-Mediated Fluorescence Quenching for Glycoprotein Analysis and Breast Cancer Diagnosis

Invited - Glycoprotein (Glycan) Markers for the Early Detection of Breast Cancer

Bovine serum albumin-gold nanoclusters protein corona stabilized polystyrene nanoparticles as dual-color fluorescent nanoprobes for breast cancer detection.

Bovine serum albumin-gold nanoclusters protein corona stabilized polystyrene nanoparticles as dual-color fluorescent nanoprobes for breast cancer detection

Using Aptamer–Nanoparticle Conjugates for Cancer Cells Detection

Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection

Quick Serological Detection of a Cancer Biomarker with an Agglutinated Supramolecular Glycoprobe

Competitive Aptasensor for the Ultrasensitive Multiplexed Detection of Cancer Biomarkers by Fluorescent Nanoparticle Counting.

CRISPR/Cas12a and aptamer-chemiluminescence based analysis for the relative abundance determination of tumor-related protein positive exosomes for breast cancer diagnosis

A Multifunctional Mesoporous Silica-Gold Nanocluster Hybrid Platform for Selective Breast Cancer Cell Detection Using a Catalytic Amplification-Based Colorimetric Assay

Versatile Aptasensor for Electrochemical Quantification of Cell Surface Glycan and Naked-Eye Tracking Glycolytic Inhibition in Living Cells.

Combined detection of breast cancer biomarkers based on plasmonic sensor of gold nanorods

Highly Sensitive Protein Detection Using Enzyme-Labeled Gold Nanoparticle Probes.

Label-free and Turn-on Aptamer Strategy for Cancer Cells Detection Based on a DNA-silver Nanocluster Fluorescence Upon Recognition-Induced Hybridization.

Specific Detection of Carcinoembryonic Antigen Based on Fluorescence Quenching of Hollow Porous Gold Nanoshells with Roughened Surface.

Nanoparticle-aptamer conjugates for cancer cell targeting and detection.

A Sensitive Fluorescence Anisotropy Method for the Direct Detection of Cancer Cells in Whole Blood Based on Aptamer-Conjugated Near-Infrared Fluorescent Nanoparticles

Peptide-conjugated Gold Nanoprobe: Intrinsic Nanozyme-Linked Immunsorbant Assay of Integrin Expression Level on Cell Membrane

Gold Nanoparticle-Based Colorimetric Assay for the Direct Detection of Cancerous Cells.

Multiplexed immunolabelling of cancer using bioconjugated plasmonic gold-silver alloy nanoparticles

Fluorescence assay for glycan expression on living cancer cells based on competitive strategy coupled with dual-functionalized nanobiocomposites.